Buradasınız

Anasayfa » Content

KRONlK BÖBREK YETERSİZLİĞİ OLAN ÇOCUKLARDA HEPATlT B VİRÜS AŞILAMASI VE SONUÇLARI

HEPATITIS B VACCINATION OF CHILDREN WITH CHRONIC RENAL FAILURE

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hepatitis B infection is one of the important problems of children with chronic renal failure. 18 hemodialysis and 10 predialysis pediatric patients seronegative for hepatitis B markers were vaccinated with Hevac B (Pasteur) theree times at one month intervals and a booster dose was given 6 months later. Sufficient antibody response was obtained in 11 hemodialysis patients (61%), and 7 predialysis patients (70%) after 3 doses of vaccination. Antibody response rates in both groups were similar. Patients with chronic renal failure should be vaccinated against hepatitis B as early as possible since they are candidates for kidney transplantation.
Bookmark/Search this post with
Abstract (Original Language): 
Kronik böbrek yetersizliği olan hastalarda Hepatit B Virus enfeksiyonları önemli bir sorun oluşturmaktadır. Hepatit B antikor ve antijenleri taşımayan hemodiyaliz tedavisi gören 18 hastaya ve prediyaliz dönemdeki 10 kronik böbrek yetersizlikli hastaya birer ay ara ile 3 doz, 5mikrog (İmi) dozunda HevacB (Pasteur) aşısı uygulandı. 6 ay sonra rapelyapıldı. 3 doz aşılama sonrası 11 hemodiyaliz hastasında (%61) ve 7prediyaliz dönemdeki hastada (%70) yeterli antikor yanıtı elde edildi. Antikor yanıt yüzdesi yönünden hemodiyaliz ve prediyaliz grupları arasında istatistiksel anlamlı fark bulunmadı. Kronik böbrek yetersizlikli hastaların mümkün olan en erken dönemde Hepatit B aşı progra¬mına alınması, transplantasyon adayı olan bu grupta Hepatit B virüs enfeksiyonunu ve HBsAg taşıyıcı sayı¬sını azaltmada yararlı olacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_51.pdf
  • 2
59-62
  • Turkish

REFERENCES

References: 

1- Sutnick Al, Millman I, London WT, et al: The role of Australia antigen in viral hepatitis and other diseases. Annu Rev Med 23:161,1972.
2- Lefebure AF, Verpooten GA, Couttenye MM, et al: Hepatitis B vaccination after renal transplantation. Vaccine 11:397, 1993.
3- Bayer EA, Wilchek M: The use of the avidincomplex as a tool in a molecular biology. Biochem Anal 26:1,1980.
4- Drouet J, Charrier G, Courouce AM: New enzyme immunoassays for HBsAG screening and anti HBs titration. Ann Biol Clin 43:702, 1985.
5- Krugman S, Giles JP: Viral hepatitis type B (MS-2
strain):Further observations on natural history and
prevention. N Eng J Med 288:755,1973.
6- Krugman S, Giles JP:Hammond J: Viral hepatitis type B (Ms-strain):studies on immunization.JAMA 217:41, 1971.
7- Szmuness W, Stevens CE, Harley ES, et al: Hepatitis B vaccine, demonstration of efficacy in a controlled clinical trial
in the United States. N Eng J Med 303:833,1980.
8- Maupqas P, Goudeau A, Coursaget P, et al: Immunization against hepatitis B in man;a pilot study of two years duration. In Viral Hepatitis-1981 International Symposium edited by
Uyas GN, Cohen SN, SCHmid R. Philadelphia, Franklin
61
. Institue Press, 1978,pp. 539-556.
9- Guesry PR, Adamowicz P, Jungers P, et al : Vaccination against hepatitis B in high risk hemodialysis unitsia double-blind study.İn Viral Hepatitis edited by Szumuness W, Alter HJ, Maynard JE, Philadelphia, Franklin Institute Press, 1982,pp.493-507.
10- Stevens CE, Alter MJ, Tayler PE, et al: Hepatitis B vaccine in patients receiving hemodialysis. N Eng J Med 311:469,1984.
11- Köhler H, Arnold W, Renschin G, et al: Active B vaccination of dialysis patients and medical staff. Kidney Int 25:124,1984.
12.Benhamou E, Courouce AM, Jungers P,et al: Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21:143, 1984.
13- Bramweil SP, Tsakirias DJ, Briggs JD, et al: Dinitrochlorobenzene skin testing predicts response to hepatitis B vaccine in dialysis patients. Lancet 1:1412, 1985.
14-
Bozfakıoğl
u S, Ark E, Ökten A et al: Hemodiyaliz hastalarının hepatit B aşısı ile aktif immünizasyonu. İst.Tıp Fak. Mecmuası 55 (3): 341, 1992.
15- Bak M, Aksu N, Kabasakal C, et al: Hemodiyaliz hastalarında hepatit B. hepatit C enfeksiyonu ve hepatit B aşı uygulaması. İst.Çocuk Kliniği Derg 28(4):229, 1993.
16- Bommer J, Ritz E,Andrassy K,et al:Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc 20:161,1983.
17- Donati D, Gastaldi L:Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination.Nephron 50: 133,1988.
18- Grob PJ,Binswanger U, Blumbertg A,et al: Thymopentin as an adjuvant to hepatitis B vaccination. Results from theree
double-blind studies. Surv Immunol Res 4 (Suppl l):107,1985.
19- Kuriyama S, Tsujii T, Ishizaka S, et al:Enhancing effects of oral adjuvants on anti HBs responses induced by hepatitis B vaccine. Clin Exp Immunol 72:383, 1988.
20- Przewlocki G, Avdibert E, Jolivet M, et al: Production of antibodies recognizing a hepatitis B virus (HBV) surface antigen by administration of murabutide associated to a synthetic pre-S HBV peptide conjugated to a toxoid carrier. Biochem Biophys Res Commun 140:557,1986.
21- Grob PJ, joller-Jemelka HI, Binswanger U, et al:Interferon as an adjuvant for hepatitis B vaccination in non-and-low responder populations. EURj Clin Microbiol 3:195, 1984.
22- MEuer SC.Kohler H, Meyer Zum Buschenfelde KH:
Monocyte defect in hemodialysis patients supports nonresponsiveness to hepatitis B vaccination and development of HBsAg carrier state. İn Viral Hepatitis and Liver Diseases edited by Zucherman AJ.New York, Alan Rliss, 1988, pp.711-713.
23- Meuer SC,Dumann H, Meyer Zum Buschenfelde HK, et al:Low-dose interleukin induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15,1989.
24- Neurath AR, Kent SB, Parker K, et al:Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 4:35-1986.
25- Itoh Y,Takai E, ohnuma H, et al:A synthetic peptide vaccine involving the product of the preS (2) region of the hepatitis B virus DNA:protective efficacy in chimpanzees.Proc Nati Acad Sci USA 83:9174,1986.
62

Thank you for copying data from http://www.arastirmax.com